Related Experiment Video

Updated: Jun 17, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.9K

Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes

Chayakrit Krittanawong1, Tania Ahuja2, Zhen Wang3,4

  • 1From Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY.

Critical Pathways in Cardiology
|August 12, 2024
PubMed

Insights

Bivalirudin is a safer anticoagulant than unfractionated heparin during percutaneous coronary intervention for acute coronary syndromes, reducing major bleeding risks. This meta-analysis confirms bivalirudin

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Outcomes of unfractionated heparin versus bivalirudin anticoagulation during percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) are not definitively established.
  • Existing data comparing these anticoagulants in ACS patients undergoing PCI requires systematic evaluation to clarify safety and efficacy profiles.

Purpose of the Study:

  • To systematically analyze and compare PCI outcomes between unfractionated heparin and bivalirudin in patients with acute coronary syndromes.
  • To determine if bivalirudin offers a different safety profile, particularly concerning bleeding events, compared to unfractionated heparin in this patient population.

Main Methods:

  • A systematic literature search was conducted across major databases (Ovid MEDLINE, Embase, Cochrane, Scopus, Web of Science) from 1966 to January 2024.
  • Ten prospective trials involving 42,253 patients with ACS undergoing PCI were included in the meta-analysis.
  • Random-effects meta-analyses were employed to pool data and assess outcomes, with independent data review and consensus for conflict resolution.

Main Results:

  • Unfractionated heparin was associated with significantly higher risks of major bleeding (RR: 1.68-1.87), non-access site complications (RR: 4.6), cardiovascular death (RR: 1.26), and thrombocytopenia (RR: 1.67) compared to bivalirudin.
  • No significant differences were observed between the two anticoagulants regarding all-cause mortality, major adverse cardiovascular events, stroke, reinfarction, or target vessel revascularization.
  • Specific bleeding outcomes, including trial-defined major bleeding and thrombolysis in myocardial infarction (TIMI) major bleeding, were notably higher with unfractionated heparin.

Conclusions:

  • Bivalirudin significantly reduces major bleeding events when used for anticoagulation during PCI in patients with acute coronary syndromes.
  • The use of bivalirudin in this context is not associated with an increased risk of stent thrombosis or major adverse cardiovascular events compared to unfractionated heparin.
  • These findings support bivalirudin as a preferred anticoagulant option for ACS patients undergoing PCI, emphasizing its favorable bleeding profile.
Abstract

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.4K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
474
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia01:16

Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia

Intravenous regional anesthesia or the Bier block technique is used to anesthetize a specific limb or extremity. It uses exsanguinated or blood-drained vessels to transport local anesthetics or LAs to the peripheral nerve trunks. Lidocaine without vasoconstrictors like epinephrine is most commonly used for this technique. Other drugs used are prilocaine, ropivacaine, and chloroprocaine. Bupivacaine is not recommended for this technique due to its high cardiac toxicity.
One of the advantages of...
381